Literature DB >> 30032673

Comparative study of the effect of bilastine and cetirizine on cognitive functions at ground level and at an altitude of 4,000 m simulated in hypobaric chamber: a randomized, double-blind, placebo-controlled, cross-over study.

Ákos Reményi1, Andor Grósz2, Sándor András Szabó2,3, Zsolt Tótka2, Dávid Molnár1, Frigyes Helfferich1.   

Abstract

INTRODUCTION: Antihistamines are easily accessible and cover the vast majority of the medical therapy of allergic rhinitis. However, their systemic administration may more frequently associate with their well-known side-effect, sedation, which is a serious problem in persons in safety-critical jobs such as aviation. We have a poor understanding whether a non-sedative antihistamine has an impact on vigilance when hypobaric hypoxia occurs during flight.
METHODS: In this randomized, placebo-controlled, double-blind, cross-over study the effect of 20 mg bilastine was compared to 10 mg cetirizine and to placebo (20 mg pyridoxine) in 33 individuals at ground level and at 4,000 m altitude simulated in hypobaric chamber. Levels of vigilance, ultrashort memory, combined distributive attention, monotony tolerance and peripheral blood oxygen saturation (SpO2) were assessed.
RESULTS: Bilastine did not impair the tested abilities in comparison with the control groups either at ground level or hypobaric hypoxia. Administration of cetirizine increased the number of errors at ground level. At the simulated altitude, already impaired results were additionally demonstrated with regards to the distributive attention test.
CONCLUSIONS: From the two examined antihistamines, bilastine should be the preferred medication for by individuals who require constant attention and are exposed to hypobaric hypoxia.

Entities:  

Keywords:  Antihistamine; attention; aviation; cognitive capability; hypobaric hypoxia; sedation; vigilance

Mesh:

Substances:

Year:  2018        PMID: 30032673     DOI: 10.1080/14740338.2018.1502268

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  3 in total

Review 1.  Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions.

Authors:  Amalia Leceta; Aintzane García; Ander Sologuren; Cristina Campo
Journal:  Drugs Context       Date:  2021-08-10

Review 2.  Efficacy and Safety of Bilastine in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis.

Authors:  Aranjit Singh Randhawa; Norhayati Mohd Noor; Mohd Khairi Md Daud; Baharudin Abdullah
Journal:  Front Pharmacol       Date:  2022-01-10       Impact factor: 5.810

Review 3.  The safety and tolerability profile of bilastine for chronic urticaria in children.

Authors:  Nikolaos G Papadopoulos; Torsten Zuberbier
Journal:  Clin Transl Allergy       Date:  2019-10-23       Impact factor: 5.871

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.